# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price t...
Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.
Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(65.90) per share which missed the analyst consensus estimate ...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.